PDCD4-induced oxidative stress through FGR/NF-κB axis in rectal cancer radiotherapy-induced AKI

Qiang Ma1, Lu Zheng2, Hao Cheng1

  • 1Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230000, PR China.

Insights

Programmed cell death protein 4 (PDCD4) promotes radiotherapy-induced acute kidney injury (AKI) in rectal cancer by activating FGR/NF-κB signaling and oxidative stress. Silencing PDCD4 alleviates AKI, suggesting a therapeutic target.

Area of Science:

  • Oncology
  • Nephrology
  • Molecular Biology

Background:

  • Radiotherapy for rectal cancer can cause acute kidney injury (AKI).
  • The molecular mechanisms underlying radiotherapy-induced AKI remain incompletely understood.
  • Programmed cell death protein 4 (PDCD4) is implicated in cellular stress responses.

Purpose of the Study:

  • To elucidate the role of PDCD4 in radiotherapy-induced AKI in rectal cancer.
  • To investigate the involvement of FGR/NF-κB signaling and oxidative stress in PDCD4-mediated AKI.
  • To explore PDCD4 as a potential therapeutic target for mitigating kidney damage.

Main Methods:

  • Bioinformatic analysis of GEO datasets (GSE90627, GSE145085) to identify differentially expressed genes.
  • Establishment of in vitro (HK-2 cells) and in vivo (BALB/c mice) models of radiotherapy-induced AKI.
  • RT-qPCR, Western blotting, CCK-8 assay, flow cytometry, KIM-1, TAS, and TOS measurements to assess gene/protein expression, cell viability, apoptosis, and oxidative stress.

Main Results:

  • PDCD4 expression was upregulated in AKI.
  • PDCD4 promoted renal tubular cell apoptosis and oxidative stress by activating FGR and the NF-κB pathway.
  • Silencing PDCD4 significantly attenuated radiotherapy-induced AKI in both in vitro and in vivo models.
  • PDCD4 activation of FGR/NF-κB signaling and oxidative stress was confirmed in vivo.

Conclusions:

  • PDCD4 plays a critical role in inducing radiotherapy-induced AKI in rectal cancer.
  • The FGR/NF-κB signaling pathway and oxidative stress are key mediators of PDCD4's detrimental effects on the kidney.
  • Targeting PDCD4 may offer a novel strategy to prevent or treat kidney injury following rectal cancer radiotherapy.